1. Search Result
Search Result
Results for "

calcium release

" in MedChemExpress (MCE) Product Catalog:

137

阻害剤およびアゴニスト

2

蛍光色素

6

生化学アッセイ試薬

12

ペプチド

1

阻害性抗体

22

天然物

6

同位体標識化合物

1

抗体

2

オリゴヌクレオチド

製品番号 製品名 Target 研究分野 構造式
  • HY-12542
    Dantrolene
    10+ Cited Publications

    F 368

    Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene is also a calcium channel protein inhibitor. Dantrolene inhibits the release of Ca 2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties .
    Dantrolene
  • HY-W010950
    Flecainide
    3 Publications Verification

    Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
    Flecainide
  • HY-14657
    Dantrolene sodium
    10+ Cited Publications

    F 440

    Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease
    Dantrolene sodium is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium is also a calcium channel protein inhibitor. Dantrolene sodium inhibits the release of Ca 2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties .
    Dantrolene sodium
  • HY-P3029
    Phospholipase A2
    1 Publications Verification

    PLA2

    Phospholipase Cardiovascular Disease Inflammation/Immunology
    Phospholipase A2 (PLA2) is a calcium-dependent, heat-stable enzyme that catalyzes the hydrolysis of glycerophospholipids at the sn-2 position of cellular membranes, thereby releasing Arachidonic Acid (AA) (HY-109590). Phospholipase A2 is a key mediator in the biosynthesis of pro-inflammatory lipid mediators, critically involved in inflammatory processes. Phospholipase A2 can be used for cardiovascular and inflammatory diseases research .
    Phospholipase A2
  • HY-101942
    Zegocractin
    15+ Cited Publications

    CM-4620

    CRAC Channel Neurological Disease
    Zegocractin (CM-4620) is a calcium-release activated calcium-channel (CRAC channel) inhibitor, with IC50s of 119 nM and 895 nM for Orai1/STIM1 and Orai2/STIM1 channels, respectively .
    Zegocractin
  • HY-15277
    AM966
    15+ Cited Publications

    LPL Receptor Inflammation/Immunology
    AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
    AM966
  • HY-100403
    Ro 67-7476
    Maximum Cited Publications
    23 Publications Verification

    mGluR Cancer
    Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
    Ro 67-7476
  • HY-100430
    CCF642
    1 Publications Verification

    Apoptosis PDI Cancer
    CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity .
    CCF642
  • HY-17436

    Calcium Channel Cardiovascular Disease Cancer
    Clevidipine is a selective, short-acting L-type calcium channel antagonist with an IC50 of 7.1 nM. Clevidipine can competitively bind to calcium channels and exert rapid vasoselective vasodilation by blocking the influx of extracellular calcium ions, thereby reducing peripheral vascular resistance and effectively controlling acute severe hypertension. Clevidipine can also protect the myocardium from reperfusion injury by promoting the release of nitric oxide (NO). Clevidipine can be used in the research of acute hypertension, perioperative blood pressure management, and myocardial ischemia-reperfusion injury .
    Clevidipine
  • HY-12542A

    Dantrolene sodium hydrate

    Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease
    Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium hemiheptahydrate is also a calcium channel protein inhibitor. Dantrolene sodium hemiheptahydrate inhibits the release of Ca 2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium hemiheptahydrate offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties .
    Dantrolene sodium hemiheptahydrate
  • HY-109804
    CORM-401
    10+ Cited Publications

    Reactive Oxygen Species (ROS) Inflammation/Immunology
    CORM-401 is an oxidant-sensitive CO-releasing molecule. CORM-401 induces NO increase in the regulation of endothelial calcium signalling. CORM-401 reduces TNF-α/CHX and H2O2-induced ROS production. CORM-401 uncouples mitochondrial respiration and inhibits glycolysis .
    CORM-401
  • HY-B0473

    Amethocaine hydrochloride

    Environmental Pollutants Calcium Channel Neurological Disease
    Tetracaine hydrochloride (Amethocaine hydrochloride) is a calcium channel protein inhibitor and blocks voltage-sensitive release of Ca 2+ from sarcoplasmic reticulum. Tetracaine hydrochloride is mainly used topically in ophthalmology and as an antipruritic .
    Tetracaine hydrochloride
  • HY-B1263

    Environmental Pollutants Bacterial Fungal Infection Neurological Disease
    Chlorobutanol is an orally active and potent inhibitor of platelet aggregation and release and a pharmaceutical preservative with antibacterial activity. Chlorobutanol inhibits thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin. Chlorobutanol is active against a wide variety of Gram-positive and Gram-negative bacteria, and several mold spores and fungi. Chlorobutanol is widely used in food and cosmetic industry .
    Chlorobutanol
  • HY-N7395
    Cyclic ADP-​ribose
    1 Publications Verification

    cADPR

    Calcium Channel TRP Channel Endogenous Metabolite Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology
    Cyclic ADP-ribose (cADPR) is a potent second messenger for calcium mobilization that is synthesized from NAD + by an ADP-ribosyl cyclase. Cyclic ADP-ribose increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels .
    Cyclic ADP-​ribose
  • HY-W039315

    Biochemical Assay Reagents Metabolic Disease
    2,5-Anhydro-D-mannitol, 97% is an antimetabolic fructose analogue. 2,5-Anhydro-D-mannitol, 97% depletes intracellular ATP, reduces oxygen consumption, regulates substrate oxidation, increases phosphomonoester levels, decreases inorganic phosphate levels, and promotes the release of intracellular calcium from intracellular calcium stores via phospholipase C-dependent activity in hepatocytes .
    2,5-Anhydro-D-mannitol, 97%
  • HY-101237

    Diheptylviologen dibromide

    Calcium Channel Cardiovascular Disease Neurological Disease
    DHBP dibromide is an inhibitor for calcium release and a muscle relaxant.
    DHBP dibromide
  • HY-118069
    (R)-ZINC-3573
    1 Publications Verification

    Mas-related G-protein-coupled Receptor (MRGPR) Infection
    (R)-ZINC-3573 is a selective Mas-related G protein-coupled receptor X2 (MRGPRX2) agonist with an EC50 value of 740 nM. (R)-ZINC-3573 can be used as a MRGPRX2 probe for the research of pain and itch .
    (R)-ZINC-3573
  • HY-P1080
    ω-Agatoxin IVA
    1 Publications Verification

    Calcium Channel Cardiovascular Disease Neurological Disease
    ω-Agatoxin IVA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50 values of 2 nM and 90 nM. ω-Agatoxin IVA inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA inhibits Capsaicin (HY-10448)-induced CGRP release and vasodilation. ω-Agatoxin IVA can be used for the research of neurological and cardiovascular disease .
    ω-Agatoxin IVA
  • HY-B1231

    RP-2831 hydrochloride

    Adrenergic Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Heptaminol (RP-2831) hydrochloride is a vasoconstrictor used in the study of hypotension, especially orthostatic hypotension. Heptaminol is also a skin cancer proliferation inhibitor that inhibits immune inflammation induced by the tumor promoting factor 12-O-tetradecanoylphorbol-13-acetate (TPA) in an NO-dependent manner. Heptaminol also acts as a sympathomimetic amine, exerting indirect sympathetic effects. Heptaminol is also an antagonist of catecholamine release and uptake and can increase intracellular free calcium levels .
    Heptaminol hydrochloride
  • HY-W145486

    Environmental Pollutants Biochemical Assay Reagents Neurological Disease Metabolic Disease Inflammation/Immunology
    Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .
    Calcium gluconate
  • HY-N4323
    14-Deoxyandrographolide
    1 Publications Verification

    Calcium Channel Apoptosis Caspase Neurological Disease Metabolic Disease
    14-Deoxyandrographolide is a diterpene with calcium channel blocking activity and acts as a uterine smooth muscle relaxant. 14-Deoxyandrographolide stimulates the release of nitric oxide (NO) in endothelial cells. 14-Deoxyandrographolide gradually desensitizes liver cells to TNF-α mediated apoptosis by inducing the release of TNFRSF1A .
    14-Deoxyandrographolide
  • HY-121885
    LMD-009
    2 Publications Verification

    CCR Metabolic Disease Endocrinology
    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM .
    LMD-009
  • HY-113920A
    Azumolene
    3 Publications Verification

    EU4093 free base

    Calcium Channel Metabolic Disease
    Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. Azumolene is a ryanodine receptor (RyR) modulator and inhibits the calcium-release through ryanodine receptor. Azumolene can be used for malignant hyperthermia research .
    Azumolene
  • HY-W010950A
    Flecainide hydrochloride
    3 Publications Verification

    Potassium Channel Sodium Channel Cardiovascular Disease
    Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
    Flecainide hydrochloride
  • HY-120986

    (S)-BEL; (S,E)-Bromoenol lactone

    Phospholipase Inflammation/Immunology
    (S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase A2β (iPLA2β) that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC50 of 2 µM .
    (S)-Bromoenol lactone
  • HY-13954
    A 839977
    1 Publications Verification

    P2X Receptor Neurological Disease Inflammation/Immunology
    A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
    A 839977
  • HY-142117

    Calcium Channel Chloride Channel Others
    Adenophostin A is an IP3 receptor (inositol 1,4,5-trisphosphate receptors) modulator and Ca 2+ releaser, with an IC50 of 1.3 nM, an EC50 of 1.4 nM, and a Ki of 0.18 nM in rats, and an IC50 of 0.95 nM in humans. Adenophostin A activates IP3 receptors, stimulates Ca 2+ release from intracellular stores and microsomes, inhibits the binding of [ 3H]IP3 to plasma membrane receptors, and activates chloride channels. Adenophostin A resists phosphorylation and dephosphorylation by IP3 metabolic enzymes to maintain its activity, and increases cytoplasmic [Ca 2+] levels via calcium mobilization from the endoplasmic reticulum of vascular smooth muscle cells. Adenophostin A is applicable to research related to hemorrhagic shock .
    Adenophostin A
  • HY-172458
    Z-3578
    1 Publications Verification

    Mas-related G-protein-coupled Receptor (MRGPR) TNF Receptor Inflammation/Immunology
    Z-3578 is an orally active small-molecule antagonist of MrgX2 with potent antipseudoallergic activity, exhibiting a KD value of 729 nM. Z-3578 effectively inhibits mast cell degranulation induced by substance P (SP) and C48/80, suppresses the release of β-hexosaminidase, significantly reduces the release of histamine and TNF-α, and decreases intracellular calcium flux. In a mouse pseudoallergy model, Z-3578 significantly alleviates paw swelling and dye extravasation, and reduces serum histamine levels. Z-3578 can be used for the study of pseudoallergic reactions .
    Z-3578
  • HY-B0265A

    (R)-BAY-e 9736

    Calcium Channel Cardiovascular Disease Neurological Disease
    (R)-Nimodipine ((R)-BAY-e 9736) is an orally active, blood-brain barrier-permeable L-type calcium channel blocker with an IC50 of 5 nM. (R)-Nimodipine inhibits corticosterone release by blocking calcium channels on the hypothalamic-pituitary-adrenal axis, thereby reversing immobilization stress-induced memory impairment and behavioral abnormalities. (R)-Nimodipine is widely used in studies related to aneurysmal subarachnoid hemorrhage, cerebral ischemia, epilepsy, age-related degenerative neurological diseases, and alcohol intoxication .
    (R)-Nimodipine
  • HY-N7491A

    Calcium Channel Cancer
    ent-(+)-verticilide is a potent and selective inhibitor of cardiac ryanodine receptor (RyR2) calcium release channels with antiarrhythmic activity. ent-(+)-verticilide inhibits RyR2-mediated diastolic Ca2+ leak and exhibits higher potency and a distinct mechanism of action compared with theDantrolene and Tetracaine. ent-(+)-verticilide is a useful tool to investigate the therapeutic potential of targeting RyR2 hyperactivity in heart and brain pathologies .
    Ent-(+)-Verticilide
  • HY-120967A

    p38 MAPK Akt Interleukin Related Cancer
    (2S)-OMPT, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .
    (2S)-OMPT
  • HY-B1559

    Environmental Pollutants Apoptosis Infection Cancer
    Allethrin, a pyrethroid insecticide is a major mosquito repellent agent. Allethrin induces oxidative stress, apoptosis and calcium release in rat testicular carcinoma cells (LC540). Allethrin induces BCL-2, caspase-3 activation and release of intracellular calcium .
    Allethrin
  • HY-113040A

    17(R),18(S)-EETeTr

    Calcium Channel Cardiovascular Disease
    (17R,18S)-Epoxyeicosatetraenoic acid (17 (R),18 (S)-EETeTr) is a physiologically active fatty acid metabolite and also a vasodilator targeting BKα. (17R,18S)-Epoxyeicosatetraenoic acid activates the outward potassium current mediated by BK channels, and this effect is independent of the BKβ1 subunit, intracellular/extracellular calcium levels, and sarcoplasmic reticulum calcium release regulated by RyR3. (17R,18S)-Epoxyeicosatetraenoic acid is produced by the epoxidation of eicosapentaenoic acid mediated by CYP1A1 variants. (17R,18S)-Epoxyeicosatetraenoic acid is applicable to research related to arrhythmia .
    (17R,18S)-Epoxyeicosatetraenoic acid
  • HY-126789

    Biochemical Assay Reagents Metabolic Disease
    DM-Nitrophen is a photolabile caged calcium compound that acts as a calcium releaser. DM-Nitrophen binds Ca 2+ with high affinity and Mg 2+ with considerable affinity before photolysis. DM-Nitrophen releases Ca 2+ into the cytosol upon ultraviolet light irradiation. DM-Nitrophen induces calcium concentration pulses, triggers cytosolic calcium transients, promotes calcium-dependent exocytosis. DM-Nitrophen can be used for the research of calcium-dependent cellular processes .
    DM-Nitrophen
  • HY-P3789

    GnRH Receptor Metabolic Disease
    Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor .
    Prolactin-Releasing Peptide (12-31), rat
  • HY-N7395A
    Cyclic ADP-​ribose ammonium
    1 Publications Verification

    cADPR ammonium

    Calcium Channel TRP Channel Endogenous Metabolite Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology
    Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for calcium mobilization that is synthesized from NAD + by an ADP-ribosyl cyclase. Cyclic ADP-ribose ammonium increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels .
    Cyclic ADP-​ribose ammonium
  • HY-103059

    Calcium Channel Cardiovascular Disease
    SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC50 value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias .
    SOICR-IN-1
  • HY-137672A

    2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate

    Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.
    2',3'-Cyclic NADP disodium
  • HY-134299

    8-(4-Chlorophenylthio)-cAMP-AM

    Ras PKA Cardiovascular Disease Metabolic Disease Cancer
    8-CPT-cAMP-AM (8-(4-Chlorophenylthio)-cAMP-AM) is an Epac/PKA activator. 8-CPT-cAMP-AM potentiates glucose-dependent first- and second-phase insulin secretion, induces β-cell depolarization, modulates intracellular calcium via influx and ryanodine-sensitive store mobilization, and facilitates calcium-induced calcium release resistant to PKA inhibition. 8-CPT-cAMP-AM can be used for the research of cardiac hypertrophy, diabetic cardiomyopathy, and melanoma .
    8-CPT-cAMP-AM
  • HY-B2200

    Tricalcium dicitrate tetrahydrate, 99%

    Environmental Pollutants Biochemical Assay Reagents Calcium Channel Metabolic Disease
    Calcium citrate tetrahydrate, 99% exhibits the ability to release more calcium ions in a short time therefore allowing a high activity, and a high concentration of calcium ions that can stimulate bone formation .
    Calcium citrate tetrahydrate, 99%
  • HY-103071

    CRAC Channel Inflammation/Immunology
    GSK-5503A is a calcium-release activated calcium (CRAC) channel blocker. GSK-5503A effectively inhibits stromal interaction molecule 1 (STIM1) mediated Orai1 and Orai3 currents in vitro. GSK-5503A can be used for the research of asthma and allergic disorders .
    GSK-5503A
  • HY-108335
    Sipatrigine
    1 Publications Verification

    619C89; BW 619C89

    Sodium Channel Calcium Channel Neurological Disease
    Sipatrigine (619C89), a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has the potential in the study for focal cerebral ischemia and stroke .
    Sipatrigine
  • HY-175515

    5-HT Receptor Neurological Disease
    5-HT2C agonist-11 (Compound 1) is an orally active, brain-penetrant and selective 5-HT2C receptor agonist (EC50=15 nM). 5-HT2C agonist-11 activates the Gq protein signaling pathway, promoting intracellular calcium release. 5-HT2C agonist-11 is promising for research of depression, post-traumatic stress disorder (PTSD) and neuropathic pain .
    5-HT2C agonist-11
  • HY-126789A

    Biochemical Assay Reagents Metabolic Disease
    DM-Nitrophen tertasodium is a photolabile caged calcium compound that acts as a calcium releaser. DM-Nitrophen tertasodium binds Ca 2+ with high affinity and Mg 2+ with considerable affinity before photolysis. DM-Nitrophen tertasodium releases Ca 2+ into the cytosol upon ultraviolet light irradiation. DM-Nitrophen tertasodium induces calcium concentration pulses, triggers cytosolic calcium transients, promotes calcium-dependent exocytosis. DM-Nitrophen tertasodium can be used for the research of calcium-dependent cellular processes .
    DM-Nitrophen tertasodium
  • HY-101013

    S-Nitroso-N-acetylpenicillamine

    Fluorescent Dye Others
    D-SNAP (S-Nitroso-N-acetylpenicillamine) can Generate nitric oxide and form superoxides spontaneously under physiological conditions and is often used to probe the cell stress response and stimulate calcium-independent synaptic vesicle release.
    D-SNAP
  • HY-W010950S

    Potassium Channel Sodium Channel Isotope-Labeled Compounds Cardiovascular Disease
    Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
    Flecainide-d3
  • HY-P991651

    Fc Receptor (FcR) Inflammation/Immunology
    MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting IgE. MEDI4212 potently inhibits human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC50 of 8 nM. MEDI4212 can be used severe asthma research .
    MEDI4212
  • HY-169819

    Exosomes Calcium Channel CD28 Inflammation/Immunology
    Calcium influx inducer compound 634 is a calcium influx inducer. Calcium influx inducer compound 634 (10 µM) enhances the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Calcium influx inducer compound 634 (10 µM) also increases the levels of CD86 and CD80 on the surface of mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483 (HY-100831) .
    Calcium influx inducer compound 634
  • HY-14752

    SB 751689

    CaSR Metabolic Disease Endocrinology
    Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis .
    Ronacaleret
  • HY-15104

    SB 751689A

    CaSR Metabolic Disease Endocrinology
    Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis .
    Ronacaleret hydrochloride

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: